Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 26.7473
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 14258745720.0
- FreeCF/Share 1.0821
- PFCF 59.3578
- PE 89.3656
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS
Published: June 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 25, 2025.
Read More
HIMZ: Buy For Short-Term Gains On Hims & Hers Health, But Be Wary Of The Risks
Published: June 27, 2025 by: Seeking Alpha
Sentiment: Neutral
HIMZ offers 2x leveraged exposure to HIMS, ideal for high-risk, short-term traders seeking amplified volatility, not long-term investors. Recent HIMS volatility, including the Novo Nordisk partnership fallout, creates attractive trading opportunities for nimble investors using HIMZ. HIMS continues to innovate and expand, targeting new markets and launching products, leading to strong growth potential and future catalysts.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Hims & Hers Health, Inc. - HIMS
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Class Action Announcement for Hims & Hers Health, Inc. (HIMS): Kessler Topaz Meltzer & Check, LLP
Published: June 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
RADNOR, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
Read More
Health & Fitness Stocks to Buy as the Wellness Trend Grows
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
SFM, BODI, and HIMS are capitalizing on the booming wellness market with digital tools, nutrition, and holistic health solutions.
Read More
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy®- Hagens Berman
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , June 27, 2025 /PRNewswire/ -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. (HIMS)
Published: June 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims and Hers” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”).
Read More
Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman
Published: June 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, June 26, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company's executives. Sookdeo v.
Read More
HIMS Investors with Losses in Excess of $100K Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
Published: June 26, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Stocks on the Move: Hims & Hers Health and JetBlue
Published: June 26, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss their strategy on some stocks on the move today.
Read More
NYSE: HIMS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Hims & Hers Health, Inc. (HIMS)
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If y.
Read More
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Rosen Law Firm Urges Hims & Hers Health, Inc. (NYSE: HIMS) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Published: June 26, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025. Hims describes itself as a “U.S.-based telehealth company that offers online access to health consultations and treatments.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Ro.
Read More
Hims & Hers Health (HIMS) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Negative
The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Hims Won't Back Down From Selling Cheap Weight-Loss Shots
Published: June 26, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ending their distribution partnership over "deceptive marketing" practices. Sam Fazeli has more on "Bloomberg Open Interest.
Read More
Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy, Faces Investor Scrutiny- Hagens Berman
Published: June 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , June 25, 2025 /PRNewswire/ -- On June 23, 2025 investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares crash over 30% after Novo Nordisk announced that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers' sales and "deceptive" marketing of the weight loss drug Wegovy®. This news has prompted national shareholders rights firm Hagens Berman to open an investigation into possible violations of the securities laws.
Read More
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Published: June 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its weight loss platform with a bundled Wegovy program and tech-driven obesity care solutions.
Read More
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.
Read More
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health ( HIMS ) has been one of the market's standout growth stocks in recent years. The company has successfully built a direct-to-consumer health platform targeting conditions like hair loss, mental health, and more recently, weight loss—delivering very strong revenue growth and stock returns.
Read More
Weight Loss Woes: Hims & Hers (HIMS) Shares Under Pressure
Published: June 23, 2025 by: Schwab Network
Sentiment: Negative
Hims & Hers (HIMS) shares are reeling after Novo Nordisk (NVO) severs its weight-loss drug relationship with the telehealth company. NVO claims HIMS was marketing knock-off weight loss drugs using "deceptive promotion" tactics.
Read More
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON HIMS & HERS HEALTH, INC. (HIMS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 23, 2025, Novo Nordisk announced that it was.
Read More
NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Significant Losses to Contact the Firm
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers”). On June 23, 2025, during pre-market hours, the pharmaceutical company Novo Nordisk announced it would no longer provide Hims & Hers with direct access to its FDA-approved weight loss drug Wegovy through NovoCare Pharmacy due to.
Read More
US strikes Iran nuclear sites, Tesla shares rise, Hims & Hers falls
Published: June 23, 2025 by: Yahoo Finance
Sentiment: Neutral
Here are some of the stories covered on Market Catalysts for Monday, June 23. Stocks wavered on news that the US bombed Iranian nuclear sites.
Read More
Novo Nordisk Ends Partnership with Hims & Hers
Published: June 23, 2025 by: WSJ
Sentiment: Negative
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.
Read More
Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation – HIMS
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hims & Hers Health, Inc. (NYSE: HIMS) resulting from allegations that Hims & Hers may have issued materially misleading business information to the investing public. So What: If you purchased Hims & Hers securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti.
Read More
Top Stock Movers Now: Tesla, Hims & Hers, Wolfspeed, and More
Published: June 23, 2025 by: Investopedia
Sentiment: Neutral
U.S. equities advanced at midday as oil prices declined on doubts the weekend U.S. military strikes against Iran and possible retaliation from Iran would disrupt supplies. The Dow Jones Industrial Average, S&P 500, and Nasdaq all gained.
Read More
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Published: June 23, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.
Read More
Novo Nordisk under pressure, ends deal with Hims & Hers
Published: June 23, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637